<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04046263</url>
  </required_header>
  <id_info>
    <org_study_id>19-1027</org_study_id>
    <nct_id>NCT04046263</nct_id>
  </id_info>
  <brief_title>Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients</brief_title>
  <official_title>Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective pilot study to determine if changing the phosphate binder to sucroferric&#xD;
      oxyhydroxide for for 6 months improves disordered mineral metabolism and nutrition status in&#xD;
      peritoneal dialysis patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Actual">September 30, 2021</completion_date>
  <primary_completion_date type="Actual">July 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum phosphate</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in serum phosphate from baseline to 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum albumin</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in serum albumin from baseline to 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum FGF23</measure>
    <time_frame>6 months</time_frame>
    <description>Change in serum FGF23 from baseline to 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum PTH</measure>
    <time_frame>6 months</time_frame>
    <description>Change in serum PTH from baseline to 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum prealbumin</measure>
    <time_frame>6 months</time_frame>
    <description>Change in prealbumin from baseline to 6 months</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Peritoneal Dialysis Complication</condition>
  <condition>Hyperphosphatemia</condition>
  <condition>Hypoalbuminemia</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label, one arm study. Patients receive sucroferric oxyhydroxide three times daily and dose is titrated to keep serum phosphate at goal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sucroferric Oxyhydroxide Chewable Tablet</intervention_name>
    <description>Patients will be started on 1 tablet three times daily with meals and the dose will be titrated monthly in increments of 500mg (1 tablet) per day until serum phosphate is at goal</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  On peritoneal dialysis at least 3 months with a Kt/V of ≥ 1.7&#xD;
&#xD;
          -  Use of Automated Peritoneal Dialysis&#xD;
&#xD;
          -  Serum phosphate &gt; 5.5 mg/dL or &lt;5.5 mg/dL on a binder other than velphoro&#xD;
&#xD;
          -  Serum albumin ≤ 3.7 g/dL&#xD;
&#xD;
          -  Able to provide consent&#xD;
&#xD;
          -  Ability to complete self-reported questionnaire&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inadequate dialysis&#xD;
&#xD;
          -  Current use of sucroferric oxyhydroxide&#xD;
&#xD;
          -  Significant comorbid conditions that lead the investigator to conclude that life&#xD;
             expectancy is less than 6 months&#xD;
&#xD;
          -  Active malignancy&#xD;
&#xD;
          -  Recent episode of peritonitis&#xD;
&#xD;
          -  Pregnancy or planning to become pregnant&#xD;
&#xD;
          -  Anticipated kidney transplantation within 6 months&#xD;
&#xD;
          -  Factors judged to limit adherence to interventions&#xD;
&#xD;
          -  Known adverse side effect to sucroferric oxydroxide&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Colorado Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 2, 2019</study_first_submitted>
  <study_first_submitted_qc>August 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2019</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoalbuminemia</mesh_term>
    <mesh_term>Hyperphosphatemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>At the end of the study deidentified data will be available to other researchers</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data will be available at the completion of the study. Researchers must obtain PI approval</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

